Compound ID | 1813

Update compound information

Epetraborole

Synonym(s): AN3365  |  GSK 2251052  |  GSK2251052

Class: Aminoacyl-tRNA synthetase inhibitor (boron-heterocyclic leucyl-tRNA synthetase [LeuRS] inhibitor)

Spectrum of activity: Gram-positive  &  Gram-negative
Details of activity: Inhibits leucyl-tRNA synthetase (LeuRS) blocking protein synthesis, active against Enterobacteriaceae, Peudomonas aeruginosa and Mycobacterium abscessus
Combined with other compounds: Yes
Description: Synthetic compound. Rapid emergence of resistance; developed in combination for nontuberculous mycobacterium infections
Institute where first reported: AN2 Therapeutics (Anacor, GSK)
Year first mentioned: 2013
Highest developmental phase: Phase 2
Development status: Inactive (as of 2023
Reason Dropped: Phase 2 trial terminated due to resistance concerns
Chemical structure(s):
Click here for structure editor
Molecular weight: 237.06
Iso. SMILES: B1(C2=C(C=CC=C2OCCCO)[C@H](O1)CN)O
InChI Key: FXQIIDINBDJDKL-SNVBAGLBSA-N
Can. SMILES: C1=CC(=C2C(=C1)[C@@H](CN)OB2O)OCCCO
InChI: InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2/t10-/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/46836890
Guide to Pharmacology: epetraborole
Citations:
  • https://journals.asm.org/doi/10.1128/AAC.01156-21
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591879/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.